Genzyme, Isis ink $1.9B pact
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
Genzyme |
Isis Pharmaceuticals |
$1.9B deal |
The deal is for Isis' promising cardiovascular drug mipomersen, its flagship product. Genzyme is paying $175 million in an upfront fee and will buy five percent of the company. |
|
Merck |
Addex Pharmaceuticals |
$702M licensing deal |
Merck is paying $22 million up front and up to $455 million more for regulatory, sales and development milestones for ADX63365, a schizophrenia drug candidate. |
|
Pfizer |
Scil Technology |
$250M licensing deal |
Pfizer gains worldwide to an experimental osteoarthritis therapy under development at Germany's Scil Technology. Scil has been developing a cartilage specific growth factor--CD-RAP--to regenerate tissue in degenerative joints. |
|
WuXi PharmaTech |
Apptec |
$151M buyout |
WuXi gains Apptec's biologics capabilities along with U.S. market presence. |
|
Invitrogen |
CellzDirect |
$57M buyout |
CellzDirect provides R&D operations hepatocyte-based cell products and other services used to test new drugs. |
|
Pfizer |
Taisho |
$22M deal |
Japan's Taisho has granted all commercial rights to its preclinical schizophrenia drug outside of Japan to Pfizer for $22 million up front. |
|
Ipsen |
Salk Institute |
$10M |
Over the next three to five years, Ipsen will pay Salk $10 million dollars to research three disease areas: cancer biology, degenerative diseases and maladies associated with metabolic syndrome. |